ABSTRACT
In anticipation of COVID-19 vaccine deployment, we use an age-structured mathematical model to investigate the benefits of optimizing age-specific dose allocation to suppress the transmission, morbidity and mortality of SARS-CoV-2 and the associated disease, COVID-19. To minimize transmission, we find that the highest priority individuals across 179 countries are typically those between 30 and 59 years of age because of their high contact rates and higher risk of infection and disease. Conversely, morbidity and mortality are initially most effectively reduced by targeting 60+ year olds who are more likely to experience severe disease. However, when population-level coverage is sufficient — such that herd immunity can be achieved through targeted dose allocation — prioritizing middle-aged individuals becomes the most effective strategy to minimize hospitalizations and deaths. For each metric considered, we show that optimizing the allocation of vaccine doses can more than double their effectiveness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.M. is funded by a postdoctoral research fellowship from the National Health and Medical Research Council's Centre of Research Excellence in Tuberculosis Control on Both Sides of Our Border (Project ID: 1153493).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Analysis updated to incorporate: hospitalizations and deaths as additional optimization targets; updated estimates of the vaccine efficacy; and further sensitivity analysis on the relative transmissibility of asymptomatic transmitters.
Data Availability
All input data and model source code has been deposited in a recognized public source repository (GitHub, https://github.com/michaeltmeehan/covid19).